| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6114319 | SANDOZ | Compositions containing difluprednate |
May, 2019
(4 years ago) | |
|
US6114319 (Pediatric) | SANDOZ | Compositions containing difluprednate |
Nov, 2019
(4 years ago) | |
Durezol is owned by Sandoz.
Durezol contains Difluprednate.
Durezol has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Durezol are:
- US6114319
- US6114319*PED
Durezol was authorised for market use on 23 June, 2008.
Durezol is available in emulsion;ophthalmic dosage forms.
Drug patent challenges can be filed against Durezol from 23 September, 2015.
The generics of Durezol are possible to be released after 18 November, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-26) | Jun 13, 2019 |
| Orphan Drug Exclusivity(ODE) | Jun 13, 2019 |
| M(M-127) | Mar 22, 2016 |
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2013 |
| Pediatric Exclusivity(PED) | Sep 22, 2016 |
| New Indication(I-653) | Jun 13, 2015 |
Drugs and Companies using DIFLUPREDNATE ingredient
NCE-1 date: 23 September, 2015
Market Authorisation Date: 23 June, 2008
Treatment: NA
Dosage: EMULSION;OPHTHALMIC
How can I launch a generic of DUREZOL before it's drug patent expiration?
More Information on Dosage
DUREZOL family patents
